|
시장보고서
상품코드
2055260
파지 요법 시장 : 제품별, 표적 병원체별, 적응 질환별, 투여 경로별, 최종사용자별, 지역별Phage Therapy Market, By Product, By Target Pathogen, By Disease Indication, By Route of Administration, By End User, By Geography |
||||||
파지 요법 시장은 2026년 14억 2,000만 달러로 추정되고, 2033년에 21억 8,000만 달러에 이를 것으로 예상되고 있습니다. 또한, 2026-2033년 CAGR 6.3%를 기록할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 14억 2,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 6.30% | 2033년 시장 규모 예측 : | 21억 8,000만 달러 |
세계 파지 요법 시장은 세균 병원체를 특이적으로 표적화하여 파괴하는 천연 유래 바이러스인 박테리오파지를 치료에 활용함으로써, 세균 감염증과 싸우는 획기적인 접근 방식을 제시하고 있습니다. 전 세계적으로 항생제 내성이 계속 증가하는 가운데, 파지 요법은 유망한 대체 치료법으로 부상하고 있으며, 기존 항생제가 효과를 보이지 않는 다제내성 세균 감염증에 대처할 수 있는 정밀의료의 가능성을 제시하고 있습니다. 이 혁신적인 치료 접근법은 박테리오파지와 박테리아 간의 자연적인 포식자-피식자 관계를 활용하여, 이러한 미세한 존재들을 통해 유익한 미생물 군집을 유지하면서 유해한 박테리아 균주를 선택적으로 제거합니다.
이 시장에는 맞춤형 파지 칵테일, 표준화된 치료용 제제, 세균 동정 및 감수성 검사를 위한 진단 도구 등 다양한 파지 기반 제품이 포함되어 있습니다. 파지 요법의 적용 범위는 만성 상처 감염, 호흡기 감염, 요로 감염, 위장 질환 치료 등 다양한 의료 분야에 이릅니다. 규제 당국의 파지 요법법 잠재력에 대한 인식이 높아지고 연구 개발 활동에 대한 투자가 증가함에 따라, 이 시장은 상당한 성장이 예상됩니다. 의료 종사자와 제약 기업들은 전 세계적인 항생제 내성 위기에 대처하기 위한 효과적인 해결책으로 파지 요법에 대한 관심을 높이고 있으며, 견고한 치료 프로토콜을 확립하기 위해 제조 공정, 품질 관리 기준, 임상시험 방법론 분야의 혁신을 추진하고 있습니다.
시장 역학
세계 파지 요법 시장은 여러 주요 요인의 견인 속에 놀라운 성장세를 보이고 있습니다. 그중에서도 가장 두드러지는 것은 다제내성 세균 감염증에 대해 기존의 많은 치료법이 효과를 잃어가고 있다는 점, 즉 전 세계적으로 항생제 내성 위기가 심화되고 있다는 사실입니다. 세계보건기구(WHO)가 항생제 내성을 세계 공중보건 위협 상위 10대 요인 중 하나로 지정한 데 따라, 대체 치료법에 대한 연구 투자와 규제 당국의 지원이 가속화되면서 파지 요법은 중요한 해결책으로서의 입지를 굳혀가고 있습니다. 병원 내 감염, 만성 상처, 세균 바이오필름 관련 질환의 유병률 증가는 의료 종사자들이 부작용을 최소화한 표적 치료를 요구함에 따라 시장 수요를 더욱 확대시키고 있습니다. 의료 종사자와 환자들 사이에서 맞춤형 의료에 대한 인식이 높아지고 있는 데다, 파지 요법의 유효성을 입증한 임상 사례의 성공이 더해지면서 시장 확산을 지속적으로 뒷받침하고 있습니다. 그러나 시장은 파지 기반 치료법에 대한 표준화된 승인 절차가 부재한 복잡한 규제 체계 등 중대한 제약에 직면해 있으며, 이로 인해 개발 기간이 길어지고 비용도 급증하고 있습니다.
파지의 안정성, 품질 관리, 대규모 제조 공정과 관련된 제조상의 과제는 상용화에 있어 또 다른 장애물로 작용하고 있습니다. 임상 검사 데이터의 부족과 다양한 균주를 대상으로 한 광범위한 안전성 및 유효성 연구의 필요성이 시장의 급속한 확장을 저해하고 있습니다. 게다가 높은 개발 비용, 지적 재산권의 복잡성, 전문적인 보관 및 유통 인프라의 필요성 등이 중소기업의 진입 장벽이 되고 있습니다. 그럼에도 불구하고, 제약 회사와 생명공학 기업 간의 전략적 제휴, 항생제 내성 연구를 지원하는 정부의 자금 지원 계획, 수의학 및 농업 분야에서의 활용 확대를 통해 큰 기회가 존재합니다. 파지 뱅크의 등장, 설계 파지를 가능하게 하는 합성생물학의 발전, 파지와 기존 항생제를 결합한 병용 요법에 대한 수용도가 높아지고 있는 점은 시장 진출기업들에게 수익성 높은 성장 기회를 제시하고 있습니다.
본 조사의 주요 특징
- 본 조사에서는 각 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 다음의 매개변수를 바탕으로 전 세계 파지 요법 시장의 주요 기업 프로파일을 작성하였습니다. 기업 개요, 제품 포트폴리오, 주요 성과, 재무 실적, 전략
- 본 보고서의 인사이트를 활용함으로써, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 관해 정보에 기반한 의사결정을 내릴 수 있게 됩니다.
- 전 세계 파지 요법 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 분석가 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 파지 요법 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 의사결정을 수월하게 내릴 수 있습니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 파지 요법 시장 : 제품별, 2021-2033년
제5장 세계의 파지 요법 시장 : 표적 병원체별, 2021-2033년
제6장 세계의 파지 요법 시장 : 적응 질환별, 2021-2033년
제7장 세계의 파지 요법 시장 : 투여 경로별, 2021-2033년
제8장 세계의 파지 요법 시장 : 최종사용자별, 2021-2033년
제9장 세계의 파지 요법 시장 : 지역별, 2021-2033년
제10장 경쟁 구도
제11장 애널리스트의 제안
제12장 참고 문헌과 조사 방법
LSH 26.06.23Phage Therapy Market is estimated to be valued at USD 1.42 Bn in 2026 and is expected to reach USD 2.18 Bn by 2033, growing at a compound annual growth rate (CAGR) of 6.3% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1.42 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.30% | 2033 Value Projection: | USD 2.18 Bn |
The global phage therapy market represents a revolutionary approach to combating bacterial infections through the therapeutic application of bacteriophages, naturally occurring viruses that specifically target and destroy bacterial pathogens. As antibiotic resistance continues to escalate worldwide, phage therapy has emerged as a promising alternative treatment modality, offering precision medicine capabilities that can address multidrug-resistant bacterial infections where conventional antibiotics have failed. This innovative therapeutic approach leverages the natural predator-prey relationship between bacteriophages and bacteria, utilizing these microscopic entities to selectively eliminate harmful bacterial strains while preserving beneficial microbiota.
The market encompasses various phage-based products, including personalized phage cocktails, standardized therapeutic formulations, and diagnostic tools for bacterial identification and susceptibility testing. Phage therapy applications span across multiple medical domains, including treatment of chronic wound infections, respiratory tract infections, urinary tract infections, and gastrointestinal disorders. The growing recognition of phage therapy's potential by regulatory bodies, coupled with increasing investment in research and development activities, has positioned this market for substantial growth. Healthcare providers and pharmaceutical companies are increasingly exploring phage therapy as a viable solution to address the global antimicrobial resistance crisis, driving innovation in manufacturing processes, quality control standards, and clinical trial methodologies to establish robust therapeutic protocols.
Market Dynamics
The global phage therapy market is experiencing significant growth momentum driven by multiple compelling factors, with the most prominent being the escalating global crisis of antibiotic resistance that has rendered many conventional treatments ineffective against multidrug-resistant bacterial infections. The World Health Organization's classification of antimicrobial resistance as one of the top ten global public health threats has accelerated research investments and regulatory support for alternative therapeutic approaches, positioning phage therapy as a critical solution. Increasing prevalence of hospital-acquired infections, chronic wounds, and bacterial biofilm-associated diseases further amplifies market demand, as healthcare providers seek targeted treatments with minimal side effects. Growing awareness among healthcare professionals and patients about personalized medicine approaches, combined with successful clinical case studies demonstrating phage therapy efficacy, continues to drive market adoption. However, the market faces significant restraints including complex regulatory frameworks that lack standardized approval pathways for phage-based therapeutics, creating lengthy and expensive development timelines.
Manufacturing challenges related to phage stability, quality control, and large-scale production processes pose additional barriers to commercialization. Limited clinical trial data and the need for extensive safety and efficacy studies across diverse bacterial strains constrain rapid market expansion. Furthermore, high development costs, intellectual property complexities, and the requirement for specialized storage and distribution infrastructure create entry barriers for smaller companies. Nevertheless, substantial opportunities exist through strategic partnerships between pharmaceutical companies and biotechnology firms, government funding initiatives supporting antimicrobial resistance research, and expanding applications in veterinary medicine and agriculture. The emergence of phage banks, advances in synthetic biology enabling engineered phages, and growing acceptance of combination therapies integrating phages with traditional antibiotics present lucrative growth avenues for market participants.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global phage therapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Armata Pharmaceuticals Inc, BiomX Inc, Pherecydes Pharma SAS, Intralytix Inc, Locus"¯Biosciences Inc, Nextbiotics Ltd, Proteon Pharmaceuticals SA, iNtRON Biotechnology Co Ltd, Micreos BV, Eligo Bioscience SA, FAGACETAC Therapeutics (or Fagoterapia), Evolution"¯Biotechnologies Inc, Tol"¯ka"¯AI"¯Therapeutics Inc, PrecisionPhage Oy, and Obulytix Inc
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global phage therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global phage therapy market
Market Segmentation
- Product Insights (Revenue, USD Bn, 2021 - 2033)
- Monophage therapy
- Phage cocktails
- Engineered/recombinant phages
- Phage"'derived enzymes (e.g., endolysins)
- Combination products (phage + antibiotic or adjunct)
- Target Pathogen Insights (Revenue, USD Bn, 2021 - 2033)
- Gram"'negative bacteria
- Escherichia coli
- Pseudomonas aeruginosa
- Salmonella spp.
- Klebsiella pneumoniae
- Other Gram"negative bacteria
- Gram"'positive bacteria
- Staphylococcus aureus
- Streptococcus spp.
- Other Gram"positive bacteria
- Mixed/other pathogens
- Disease Indication Insights (Revenue, USD Bn, 2021 - 2033)
- Urinary tract infections (UTIs)
- Skin and wound infections
- Bone and joint/implant"'associated infections
- Respiratory tract infections (including cystic fibrosis)
- Gastrointestinal infections
- Bloodstream/sepsis infections
- Biofilm"'related chronic infections
- Other indications
- Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Oral
- Topical/dermal
- Injectable/intravenous (IV/IM)
- Inhalation/nebulized
- Local instillation (e.g., bladder, wound cavity)
- Other routes
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals and specialty clinics
- Research institutes and academic centers
- Ambulatory care/outpatient clinics
- Others (Veterinary clinics)
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Armata Pharmaceuticals Inc
- BiomX Inc
- Pherecydes Pharma SAS
- Intralytix Inc
- Locus"¯Biosciences Inc
- Nextbiotics Ltd
- Proteon Pharmaceuticals SA
- iNtRON Biotechnology Co Ltd
- Micreos BV
- Eligo Bioscience SA
- FAGACETAC Therapeutics (or Fagoterapia)
- Evolution"¯Biotechnologies Inc
- Tol"¯ka"¯AI"¯Therapeutics Inc
- PrecisionPhage Oy
- Obulytix Inc
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Phage Therapy Market, By Product
- Global Phage Therapy Market, By Target Pathogen
- Global Phage Therapy Market, By Disease Indication
- Global Phage Therapy Market, By Route of Administration
- Global Phage Therapy Market, By End User
- Global Phage Therapy Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Phage Therapy Market, By Product, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Monophage therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Phage cocktails
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Engineered/recombinant phages
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Phage"'derived enzymes (e.g., endolysins)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Combination products (phage + antibiotic or adjunct)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Global Phage Therapy Market, By Target Pathogen, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Gram"'negative bacteria
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Escherichia coli
- Pseudomonas aeruginosa
- Salmonella spp.
- Klebsiella pneumoniae
- Other Gram"negative bacteria
- Gram"'positive bacteria
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Staphylococcus aureus
- Streptococcus spp.
- Other Gram"positive bacteria
- Mixed/other pathogens
6. Global Phage Therapy Market, By Disease Indication, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Urinary tract infections (UTIs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Skin and wound infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Bone and joint/implant"'associated infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Respiratory tract infections (including cystic fibrosis)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Gastrointestinal infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Bloodstream/sepsis infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Biofilm"'related chronic infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Other indications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Phage Therapy Market, By Route of Administration, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Topical/dermal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Injectable/intravenous (IV/IM)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Inhalation/nebulized
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Local instillation (e.g., bladder, wound cavity)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Other routes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Global Phage Therapy Market, By End User, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals and specialty clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Research institutes and academic centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Ambulatory care/outpatient clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others (Veterinary clinics)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
9. Global Phage Therapy Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Product, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Target Pathogen, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Product, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Target Pathogen, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Product, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Target Pathogen, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Product, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Target Pathogen, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Product, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Target Pathogen, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Product, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Target Pathogen, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
10. Competitive Landscape
- Armata Pharmaceuticals Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- BiomX Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pherecydes Pharma SAS
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Intralytix Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Locus"¯Biosciences Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Nextbiotics Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Proteon Pharmaceuticals SA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- iNtRON Biotechnology Co Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Micreos BV
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eligo Bioscience SA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- FAGACETAC Therapeutics (or Fagoterapia)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Evolution"¯Biotechnologies Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Tol"¯ka"¯AI"¯Therapeutics Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- PrecisionPhage Oy
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Obulytix Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About us
